Company profile: SalioGen
1.1 - Company Overview
Company description
- Provider of non-viral Gene Coding technology enabling precise integration of large or multiple whole genes without double-strand breaks or guide RNA, and of programs including SGT-1001 for Stargardt disease, one-time genetic medicines for cystic fibrosis, CAR-T cell engineering for cancer and autoimmune diseases with tissue-specific integration, and therapies for inherited retinal diseases.
Products and services
- SGT-1001: A one-time, non-viral development candidate that uses Gene Coding technology to treat Stargardt disease by integrating a healthy copy of the ABCA4 gene
- Gene Coding Technology: A non-viral method integrating large or multiple whole genes into the genome at precise locations without double-strand breaks or guide RNA for potentially curative therapies in inherited disorders
- Cystic Fibrosis Therapy Development: Developing non-viral genetic medicines using Gene Coding technology for cystic fibrosis, aiming to provide a one-time, permanent solution
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SalioGen
RetroSense Therapeutics
HQ: United States
Website
- Description: Provider of gene therapies for vision restoration, developing treatments to restore sight in patients with blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD), conditions for which there are currently no FDA-approved drugs to improve or restore vision.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RetroSense Therapeutics company profile →
Rocket Pharmaceuticals
HQ: United States
Website
- Description: Provider of gene therapies for rare childhood disorders, developing lentiviral and AAV vector-based programs including RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, an AAV program for Danon Disease, and gene therapies for LAD-I, PKP2 arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rocket Pharmaceuticals company profile →
Mirus Bio
HQ: United States
Website
- Description: Provider of nucleic acid-based technologies and gene transfer methods for the pharmaceutical business, including a proprietary RNAi delivery platform and tools for gene expression and biotherapeutic protein. Products include TransIT-VirusGEN for AAV/lentivirus vector production in research and clinical applications, RevIT AAV Enhancer, TransIT-LT1 transfection reagent, and GMP-grade ancillary materials for cell and gene therapy manufacturing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mirus Bio company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
EnPlusOne Biosciences
HQ: United States
Website
- Description: Provider of an ezRNA platform enabling incorporation of standard and non-standard nucleobases and their modifications, supporting installation of standard and phosphorothioated backbones, and integrating 2' modifications essential for siRNA therapeutics and novel variants. Offers 3' modifications including linkers and chain terminators for emerging RNA therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EnPlusOne Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SalioGen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SalioGen
2.2 - Growth funds investing in similar companies to SalioGen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SalioGen
4.2 - Public trading comparable groups for SalioGen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →